Log in or Sign up for Free to view tailored content for your specialty!
Hepatitis C News
Minimal monitoring program achieves SVR in hepatitis C
In a minimal monitoring – or “Minmon” – study, patients given a full regimen for hepatitis C virus and then remotely monitored achieved 95% sustained virologic response, according to a presenter at The Liver Meeting Digital Experience.
Post-HCV treatment liver stiffness linked with adverse outcomes
Higher fibroscan liver stiffness after hepatitis C antiviral treatment was associated with the development of decompensated cirrhosis, according to study results.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: No ‘hard-to-reach’ patients in HCV, just ‘hardly reached’
In this exclusive video, Joss O’Loan, MBBS, from the Hepatitis C Kombi Clinic in Brisbane, Australia, discusses two studies presented at The Digital International Liver Congress on HCV elimination programs using Epclusa.
DAAs provide ‘dramatic’ improvement in outcomes for pediatric patients with HCV
Direct-acting antivirals first received approval for use in adults with hepatitis C in 2013. They were approved for use in children several years later, in 2017.
COVID-19 leads to challenges ‘at every single step’ of HCV care cascade
The COVID-19 pandemic has had “a tremendously negative impact” on efforts to eliminate hepatitis C, according to Ricardo Franco, MD.
DAAs change liver transplant landscape, use of HCV-positive organs
Direct-acting antivirals for hepatitis C have not only led to a cure for the virus — they’ve also changed the paradigm in liver transplantation. This includes the transplantation of HCV-positive organs into HCV-negative recipients.
DAAs lower risk for death among patients with HCV, regardless of cirrhosis
Treatment with direct-acting antivirals was associated with decreased mortality among a sample of more than 50,000 Medicare beneficiaries with hepatitis C virus, regardless of the presence of cirrhosis, according to data published in JAMA Network Open.
HCV drugs sofosbuvir, daclatasvir show promise as potential COVID-19 treatment
Using hepatitis C drugs sofosbuvir and daclatasvir in combination with standard care to treat patients with COVID-19 resulted in better 14-day recovery rates and a shorter hospital stay, according to data presented at AIDS 2020.
HHS updates transplant guidance to improve safety, access to organs
The HHS and the U.S. Public Health Service updated the solid organ transplant guidance to evaluate donors and monitor recipients for HIV, hepatitis B virus, and hepatitis C virus infections, according to a release.
Universal screening reveals ‘striking’ HCV antibody prevalence in people born after 1965
Universal hepatitis C virus screening in EDs with the ability to opt out showed that nearly half of infections were identified in people born after 1965, according to findings published in MMWR.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read